Replicor Drug Shows Activity Against Avian Flu
Posted on: Friday, 7 April 2006, 15:01 CDT
Replicor's lead compound, REP 9, has been shown to have potent antiviral activity against avian H5N1 influenza virus in test tube studies.
The influenza virus used in the study was A/Vietnam/1203/04, a human pathogenic avian influenza isolated from a fatally infected patient. This virus is highly aggressive and replicates much more rapidly than normal strains of the influenza virus.
This initial demonstration of REP 9 in vitro activity against H5N1 was generated in collaboration with Dr Michael Holbrook at The University of Texas Medical Branch at Galveston in their level 4 biosafety facility.
REP 9 has also recently been shown to have potent antiviral activity against influenza virus strains which are resistant to the action of Tamiflu and Relenza. Both drugs are currently marketed for the therapy of influenza infections.
In previous studies, aerosol administered REP 9 was shown to prevent the spread of influenza in mice. Additional tissue culture studies have shown that REP 9 has potent antiviral activity in 20 strains of influenza A and B, demonstrating its potential application against emergent flu viruses.
REP 9 inhibits both neuraminidase and hemagglutinin, two viral proteins essential for replication.
Source: Datamonitor
Related Articles
- ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
- ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
- Achillion Reports Safety and Potent Antiviral Activity in Topline Results From Elvucitabine Phase 2 Study in HIV-Infected Patients
- R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
- Vical's DNA Vaccine Provides Complete Protection Against Avian Influenza and Demonstrates Cross-Protection Against Multiple Human Flu Strains in Animal Studies
- Phase 3 Study Results of MedImmune's Next-Generation Influenza Vaccine Suggest Better Relative Efficacy Against Matched and Mismatched Strains Compared to the Flu Shot in Young Children
- ADVENTRX Announces Thiovir Active Against H5N1 Avian Influenza Chimeric Virus Strains
- Baxter Study Verifies Inactivation of Influenza H5N1 Virus During Manufacture of Its Plasma-Derived Therapies
- Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity As Monotherapy and in Combination With PEG-INTRON(R) in Phase I Studies
- Green Tea Ingredient Protects Brain Against Alzheimer's Disease: Study
 |
 |
User Comments (0)
RSS Feeds